MARKET

GHDX

GHDX

Genomic Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

63.44
0.00
0.00%
Delisted 09:30 11/15 EST
OPEN
63.88
PREV CLOSE
63.88
HIGH
64.57
LOW
62.74
VOLUME
12.54M
TURNOVER
--
52 WEEK HIGH
86.70
52 WEEK LOW
50.77
MARKET CAP
2.38B
P/E (TTM)
43.05
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GHDX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GHDX News

  • Celgene (CELG) Hits 52-Week High, Can the Run Continue?
  • Zacks.6d ago
  • Exact Sciences completes $2.8B acquisition of Genomic Health
  • American City Business Journals.11/08 17:22
  • Why the Earnings Surprise Streak Could Continue for Genomic Health (GHDX)
  • Zacks.11/08 15:10
  • Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
  • PR Newswire.11/08 13:02

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About GHDX

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.
More

Webull offers Genomic Health, Inc. (GHDX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.